Wells Fargo & Company Begins Coverage on Savara (NASDAQ:SVRA)

Investment analysts at Wells Fargo & Company started coverage on shares of Savara (NASDAQ:SVRA) in a report issued on Friday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $8.00 price target on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 147.68% from the stock’s previous close.

SVRA has been the topic of several other reports. HC Wainwright reduced their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Thursday. Finally, Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.86.

Savara Price Performance

SVRA stock opened at $3.23 on Friday. The company has a market capitalization of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. The company has a fifty day moving average price of $3.47 and a 200-day moving average price of $3.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a 52-week low of $2.82 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). As a group, equities analysts expect that Savara will post -0.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Joseph S. Mccracken purchased 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Several hedge funds have recently bought and sold shares of SVRA. Choreo LLC acquired a new position in Savara during the second quarter worth $59,000. DRW Securities LLC purchased a new stake in Savara in the 2nd quarter valued at $62,000. Virtu Financial LLC purchased a new stake in shares of Savara in the third quarter valued at about $67,000. Principal Financial Group Inc. increased its stake in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.